Home › RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?
 

Keywords :   


RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?

2015-09-11 14:41:16| Biotech - Topix.net

Every market day, we select up to 20 of our authors' top long and short ideas, exclusively for PRO subscribers. RedHill focuses on late stage oral gastrointestinal drugs; the company has two potential blockbusters in Phase 3 studies, 9 active clinical programs in total.

Tags: is it market million

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.11Sheboygan Paint Company Names New Regional Sales Managers
08.11Irritants could disrupt U.S., Mexico trade relationship
08.11Irritants could disrupt U.S., Mexico trade relationship
08.11Atlantic Tropical Weather Outlook
08.11Eastern North Pacific Tropical Weather Outlook
08.11African swine fever, labor and trade top of mind for Canadian pork industry
08.11Tech giants dominate U.S. streaming platform market
08.11Warner Bros. Discovery adds 7.2 million DTC subscribers in 3Q 2024
More »